StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
11
Publishing Date
2022 - 06 - 06
1
2022 - 03 - 25
1
2022 - 02 - 01
1
2021 - 08 - 25
1
2021 - 07 - 12
1
2021 - 05 - 06
1
2021 - 05 - 03
1
2021 - 04 - 12
1
2021 - 01 - 20
1
2021 - 01 - 13
1
2020 - 12 - 07
1
Sector
Health technology
11
Tags
Acquired
1
Acquisition
1
Agreement
2
Als
1
Application
7
Approval
2
Arq-255
1
Asia
1
Atopic dermatitis
2
Biotech
1
Biotech-bay
3
Biotech-beach
7
Business
4
Care
2
Children
9
Clinical-trials-phase-ii
2
Clinical-trials-phase-iii
5
Collaboration
3
Commercial
2
Conference
13
Dermatitis
32
Drug
11
Enroll
4
Europe
3
Fda
9
Financial
12
Financial results
4
Grant
2
Grants
15
Health
5
Iot
7
Meeting
4
Mergers-and-acquisitions
2
N/a
120
Nasdaq
17
New drug
2
Offering
10
Phase 2
3
Phase 2b
3
Phase 3
11
Plague
9
Positive
7
Potential
8
Presentation
2
Program
2
Psoriasis
22
Report
8
Research
3
Response
2
Results
23
Study
2
Symposium
2
Therapeutics
3
Topline
4
Treatment
24
Trial
22
Trials
4
Update
5
Year
3
Zoryve
11
Entities
Abbvie inc.
30
Achieve life sciences, inc.
6
Adial pharmaceuticals, inc
11
Albireo pharma, inc.
6
Aldeyra therapeutics, inc.
11
Alnylam pharmaceuticals, inc.
23
Amgen inc.
7
Apellis pharmaceuticals, inc.
10
Arcutis biotherapeutics, inc.
11
Astrazeneca plc
7
Avadel pharmaceuticals plc
7
Bausch health companies inc.
6
Beigene, ltd.
8
Beyondspring, inc.
10
Biogen inc.
12
Biohaven pharmaceutical holding company ltd.
8
Biomarin pharmaceutical inc.
8
Brickell biotech, inc.
12
Bristol-myers squibb company
12
Cassava sciences, inc.
9
Citius pharmaceuticals, inc.
9
Coherus biosciences, inc.
13
Crinetics pharmaceuticals, inc.
8
Cyclo therapeutics inc - class a
6
Cytokinetics, incorporated
6
Dynavax technologies corporation
11
Eiger biopharmaceuticals, inc.
9
Eli lilly and company
47
Exelixis, inc.
10
Gilead sciences, inc.
9
Humanigen, inc.
9
I-mab
9
Ideaya biosciences, inc.
8
Incyte corporation
23
Inovio pharmaceuticals, inc.
8
Ionis pharmaceuticals, inc.
9
Jazz pharmaceuticals plc
7
Johnson & johnson
29
Madrigal pharmaceuticals, inc.
8
Merck & company, inc.
18
Mesoblast limited
9
Moderna, inc.
10
Myovant sciences ltd.
11
Novan, inc.
10
Novavax, inc.
13
Novocure limited
8
Ocuphire pharma inc.
8
Onconova therapeutics, inc.
7
Oramed pharmaceuticals inc.
7
Pfizer, inc.
21
Regeneron pharmaceuticals, inc.
26
Sanofi
44
Scynexis, inc.
12
Sorrento therapeutics, inc.
8
Takeda pharmaceutical company limited
19
Teva pharmaceutical industries ltd
15
Tg therapeutics, inc.
18
Tonix pharmaceuticals holding corp.
10
Veru inc.
10
Zealand pharma a/s
7
Symbols
ARQT
11
Exchanges
Nasdaq
11
Crawled Date
2022 - 06 - 06
1
2022 - 03 - 25
1
2022 - 02 - 01
1
2021 - 08 - 25
1
2021 - 07 - 12
1
2021 - 05 - 06
1
2021 - 05 - 03
1
2021 - 04 - 12
1
2021 - 01 - 20
1
2021 - 01 - 13
1
2020 - 12 - 07
1
Crawled Time
12:00
1
12:15
1
12:20
1
13:00
1
13:15
1
14:00
2
14:01
2
14:03
1
21:00
1
Source
www.arcutis.com
1
www.biospace.com
4
www.globenewswire.com
6
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Phase 3
entities :
Arcutis biotherapeutics, inc.
save search
Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
Published:
2022-06-06
(Crawled : 12:20)
- biospace.com/
ARQT
A
|
$10.23
1.29%
1.27%
2.2M
|
Health Technology
|
-50.84%
|
O:
4.65%
H:
1.24%
C:
-4.42%
topline
dermatitis
trial
positive
results
phase 3
Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting
Published:
2022-03-25
(Crawled : 12:00)
- globenewswire.com
ARQT
A
|
$10.23
1.29%
1.27%
2.2M
|
Health Technology
|
-42.91%
|
O:
-0.62%
H:
2.87%
C:
-2.22%
trials
psoriasis
phase 3
plague
Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis
Published:
2022-02-01
(Crawled : 13:00)
- arcutis.com
ARQT
A
|
$10.23
1.29%
1.27%
2.2M
|
Health Technology
|
-32.67%
|
O:
0.8%
H:
4.53%
C:
2.51%
als
dermatitis
trial
phase 3
enroll
Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis
Published:
2021-08-25
(Crawled : 14:00)
- biospace.com/
ARQT
A
|
$10.23
1.29%
1.27%
2.2M
|
Health Technology
|
-50.95%
|
O:
0.05%
H:
3.88%
C:
1.31%
treatment
potential
phase 3
trial
psoriasis
enroll
Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis
Published:
2021-07-12
(Crawled : 12:15)
- globenewswire.com
ARQT
A
|
$10.23
1.29%
1.27%
2.2M
|
Health Technology
|
-60.0%
|
O:
4.75%
H:
2.8%
C:
2.31%
treatment
potential
dermatitis
phase 3
trial
enroll
Arcutis Biotherapeutics Showcases Pivotal DERMIS-1 and -2 Phase 3 Trial Data for Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis at EADV Spring Symposium 2021
Published:
2021-05-06
(Crawled : 14:00)
- biospace.com/
ARQT
A
|
$10.23
1.29%
1.27%
2.2M
|
Health Technology
|
-69.91%
|
O:
3.5%
H:
0.0%
C:
-6.12%
phase 3
iot
trial
psoriasis
symposium
plague
Arcutis to Present New Roflumilast Cream Phase 3 Data at The European Academy of Dermatology and Venereology (EADV) Spring Symposium
Published:
2021-05-03
(Crawled : 21:00)
- biospace.com/
ARQT
A
|
$10.23
1.29%
1.27%
2.2M
|
Health Technology
|
-69.85%
|
O:
5.31%
H:
0.6%
C:
-1.5%
europe
phase 3
symposium
Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis in Pediatric Patients Between the Ages of Two and Five Years
Published:
2021-04-12
(Crawled : 13:15)
- globenewswire.com
ARQT
A
|
$10.23
1.29%
1.27%
2.2M
|
Health Technology
|
-62.06%
|
O:
0.04%
H:
3.83%
C:
1.76%
treatment
potential
dermatitis
phase 3
trial
atopic dermatitis
Arcutis to Advance Topical Roflumilast Foam (ARQ-154) into Phase 3 Development for the Treatment of Seborrheic Dermatitis
Published:
2021-01-20
(Crawled : 14:03)
- globenewswire.com
ARQT
A
|
$10.23
1.29%
1.27%
2.2M
|
Health Technology
|
-64.83%
|
O:
0.77%
H:
1.28%
C:
-2.52%
dermatitis
phase 3
treatment
Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis
Published:
2021-01-13
(Crawled : 14:01)
- globenewswire.com
ARQT
A
|
$10.23
1.29%
1.27%
2.2M
|
Health Technology
|
-63.03%
|
O:
-0.92%
H:
4.67%
C:
0.26%
dermatitis
phase 3
trial
treatment
potential
atopic dermatitis
Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
Published:
2020-12-07
(Crawled : 14:01)
- globenewswire.com
ARQT
A
|
$10.23
1.29%
1.27%
2.2M
|
Health Technology
|
-61.17%
|
O:
0.88%
H:
2.25%
C:
1.03%
phase 3
trial
potential
psoriasis
plague
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.